Overview

Comparison of Efficacy of Triple Regimen Based on Clarithromycin VS Metronidazole in Children

Status:
Recruiting

Trial end date:
2022-09-14

Target enrollment:
0

Participant gender:
All

Summary

All children from 1day to 18years of age, diagnosed with peptic ulcer disease due to H pylori at Pakistan Institute of Medical Sciences, Islamabad, from July 2020 to December 2021 will be included in the study. After informed written consent from parents/ guardians patients' bio data along with history and examination will be recorded on a proforma. They will be allocated into two groups, group A and group B randomly based on treatment regimen offered. Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI) Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI The history will include presenting symptoms along duration, remission of symptoms after therapy and clinical outcome will also be recorded.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Shaheed Zulfiqar Ali Bhutto Medical University

Treatments:

Amoxicillin
Clarithromycin
Metronidazole
Omeprazole

Criteria

Inclusion Criteria:

- 1. All children age 1-12 years having H-pylori gastritis

Exclusion Criteria:

- drug induced gastritis critically ill child